Skip to main content
. Author manuscript; available in PMC: 2010 Jun 1.
Published in final edited form as: Expert Opin Biol Ther. 2009 Jun;9(6):737–747. doi: 10.1517/14712590902988451

Table 1.

Adenovirus in clinical trials for glioma.

Gene/Prodrug Clinical Trial Reference
Replication Defective Adenovirus
Adv.RSVtk/Gancyclovir Phase I, dose escalation Trask et al, 2000 [73].
Ad-p53 (INGN 201; Advexin) Phase I, dose escalation Lang et al, 2003 [69].
IG.Ad.MLPI.TK/Gancyclovir Phase I, dose escalation Smitt et al, 2003 [64].
ADV/HSV-tk/Gancyclovir Phase I, dose escalation Germano et al, 2003 [75].
HSV-tk/Gancyclovir (Cerepro) Phase III (European Medicines Agency) Immonen et al, 2004 [76].
AdV-tk/Valacyclovir (GliAtak) Phase I, dose escalation
Phase Ib, currently ongoing		 New et al, 2008 [93].
Protocol ID: NCT00751270
AdV-tk /Valacyclovir/Radiation (GliAtak) Phase II, currently ongoing Protocol ID: NCT00589875
Replication Competent Adenovirus
Delta-24-RGD Phase I, currently ongoing Protocol ID: NCT00805376
ONYX-015 Phase I, open label, dose escalation Chiocca et al, 2004 [91].